AngioGenex, Inc. (AGGX.OB)

AngioGenex, Inc., a development stage biopharmaceutical company, engages in the research to develop anti-cancer strategies using the field of antiangiogenesis. Its programs focus on the discovery and development of orally active anti-cancer drugs that act by modulating the action of the Id proteins; the measurement of Id proteins in tumors and blood to create products for the diagnosis and prognosis of cancer; and generating proof- of-concept data in relevant preclinical models to establish that modulation of Id genes and proteins is useful to treat non-oncologic diseases. The company was founded in 1999 and is based in New York, New York.